Patient death clouds Bristol Myers fibrosis drug ahead of readout

· Health · United States

Bristol Myers Squibb disclosed a fatal liver injury and other liver-related safety events in testing of its lung disease candidate admilparant, though it is unclear whether the drug was to blame. The news shakes confidence in a new class of fibrosis drugs ahead of an upcoming readout.

Why it matters：Safety signals in a closely watched drug class can slow development across the field and reshape expectations for several companies' pipelines.

Key points

  • A limited number of liver-related safety events, including one death, were observed.
  • The disclosure came in a May amendment to a trial.
  • It is unclear whether admilparant caused the events.

Sources (original reporting)

More stories from this day